) boasts of a strong vaccine portfolio, which includes vaccines
like Infanrix/Pediarix, Rotarix, Synflorix and Cervarix. Glaxo
has a strong vaccine segment, which generated sales of £2.5
billion in the first nine months of 2013, approximately 12.5% of
the total product sales of the company.
Synflorix is approved for active immunization against pneumonia
caused by streptococcus pneumoniae in children aged between 6
weeks and 5 years in 67 countries. Apart from this, Synflorix is
also approved for active immunization against invasive disease
and acute otitis media caused by streptococcus pneumoniae in
children aged between 6 weeks and 5 years in the EU and 90 other
countries. As of now, Synflorix is not approved in the U.S. for
Glaxo is looking to expand the Synflorix label in Europe to
include the pneumonia indication. The European Medicines Agency's
Committee for Medicinal Products for Human Use has recommended
the approval of Synflorix for active immunization against
pneumonia caused by streptococcus pneumoniae in children aged
between 6 weeks and 5 years. A decision from the European
Commission is expected by Dec 31, 2013.
Glaxo, a large cap pharma company, carries a Zacks Rank #3
(Hold). We are pleased with Glaxo's pipeline development efforts.
A number of pipeline-related news is expected in the coming
quarters including the U.S. Food and Drug Administration's (FDA)
decision on UMEC/VI (target date: Dec 18, 2013) for chronic
obstructive pulmonary disease. We believe Glaxo's pipeline must
deliver since sales of many of its key products are declining due
to generic competition.
Other large-cap pharma stocks such as
Johnson and Johnson
) currently appear to be more attractive. While Roche carries a
Zacks Rank #1(Strong Buy), Bayer and Johnson and Johnson carry a
Zacks Rank #2 (Buy).
BAYER A G -ADR (BAYRY): Free Stock Analysis
GLAXOSMITHKLINE (GSK): Free Stock Analysis
JOHNSON & JOHNS (JNJ): Free Stock Analysis
ROCHE HLDG LTD (RHHBY): Get Free Report
To read this article on Zacks.com click here.